Search: (WFRF:(Lood Margareta)) >
Phase II Study of D...
Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
-
- Sorbe, Bengt (author)
- University Hospital, Örebro
-
- Graflund, Marianne (author)
- University Hospital, Örebro
-
- Horvath, György, 1942 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Sahlgrenska University Hospital
-
show more...
-
- Swahn, Marie (author)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Sahlgrenska University Hospital
-
- Boman, Karin (author)
- Umeå universitet,Onkologi,University Hospital, Umeå
-
- Bangshöj, Rene (author)
- Central Hospital Karlstad
-
- Lood, Margareta (author)
- Central Hospital Karlstad
-
- Malmström, Henric (author)
- Östergötlands Läns Landsting,Onkologiska kliniken US
-
show less...
-
(creator_code:org_t)
- Lippincott, Williams and Wilkins / Wiley-Blackwell, 2012
- 2012
- English.
-
In: International Journal of Gynecological Cancer. - : Lippincott, Williams and Wilkins / Wiley-Blackwell. - 1048-891X .- 1525-1438. ; 22:1, s. 47-53
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
https://gup.ub.gu.se...
-
show less...
Abstract
Subject headings
Close
- Objectives: The purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a series of patients with advanced-stage ovarian carcinoma treated with a first-line weekly docetaxel and 3 weekly carboplatin regimen. less thanbrgreater than less thanbrgreater thanMethods: All eligible patients were treated with intravenous docetaxel (30 mg/m(2)) on days 1, 8, and 15, and carboplatin (area under the curve, 5) on day 1; every 21 days for at least 6 cycles. less thanbrgreater than less thanbrgreater thanResults: One hundred six patients received at least one cycle of primary chemotherapy (median, 6.0; range, 1-9), and they were evaluable for toxicity assessment. Eighty-five patients had evaluable (measurable) disease and received at least 3 courses of chemotherapy and were evaluable for clinical response rate. The overall response rate was 78.8% (95% confidence interval, 70.1%-87.5%), and the biochemical response 92.8% (95% confidence interval, 87.2%-98.4%). The median progression-free survival was 12.0 months and the median overall survival was 35.3 months. Thirty-six patients (34.0%) experienced grades 3 and 4 neutropenia, which resulted in the removal of 3 patients. Six patients (5.7%) experienced grades 3 or 4 thrombocytopenia. No patients experienced grade 3 to grade 4 sensory neuropathy. Epiphora, nail changes, and fatigue were frequently recorded nonhematologic adverse effects. less thanbrgreater than less thanbrgreater thanConclusions: The tolerable hematologic toxicity (no need for colony-stimulating factors) and the low rate of neurotoxicity (only grades 1-2) and response rates in line with the standard 3-week paclitaxel-carboplatin regimen for advanced primary ovarian carcinoma after suboptimal cytoreductive surgerymake this regimen an interesting alternative in selected patients.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Ovarian cancer
- Docetaxel
- Carboplatin
- Weekly administration
- MEDICINE
- MEDICIN
- Ovarian cancer
- Docetaxel
- Carboplatin
- Weekly administration
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database